// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Clinical Outcomes Following Prophylaxis With Octocog Alfa in Patients With Moderate Hemophilia A: 8-Year Interim Read-out of the Real-world AHEAD International Study

M. Ozelo - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Antihemophilic factor recombinant

Clot Destabilisation by the Inclusion of Fibrin with Truncations in the αC-region

H. mcPherson - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Comparability of bleeding outcomes by prophylactic FVIII replacement intensity: A post-hoc analysis of a non-interventional study of men with severe hemophilia A

C. Camp - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

BMN-270

Comparative effectiveness of valoctocogene roxaparvovec and prophylactic factor VIII replacement estimated through propensity scoring

H. Liu - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

FVIII

Comparing the proportion of medical and surgical hospital inpatients requiring pharmacological thromboprophylaxis using different risk assessment models: an observational cohort study

D. Horner - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparison of effectiveness and safety of direct oral anticoagulant versus low molecular weight heparin treatment for venous thromboembolism in patients with active cancer – the OSCAR UK Study

A. Cohen - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

End stage renal disease

Heparin

Comparison of fibrinogen concentrates to cryoprecipitate in restoring clot integrity and stability against fibrinolytic degradation

C. Whyte - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Concurrent use of Tranexamic acid and hormonal therapy for the management of heavy menstrual bleeding in women

A. epstein - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tranexamic acid

Congenital Haemophilia A with very low titre inhibitor, undetectable by routine methods and presenting with discrepant factor VIII assays post treatment with recombinant FVIII

D. White - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

rFVIII

Connexins are post-translationally modified in activated platelets; potential role of calpain

A. Elgheznawy - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Correction of Coagulopathy in Trauma Haemorrhage – Still Room for Improvement. A Secondary Analysis of the ITACTIC trial

C. Lindsay - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Trauma

N/A

COVID-19 Coagulopathies – Highlights On 2020-2021 Reported Data

S. Anil Kumar - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

COVID-19 disease is associated with a hypofibrinolytic state driven by elevated plasminogen activator inhibitor-1 and its cofactor vitronectin

M. Simpson - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Fibrinogen (IV)

Crimson 1: A Phase 3 study to evaluate the efficacy and safety of subcutaneous marzeptocog alfa (activated) for on-demand treatment of bleed events in subjects with hemophilia A or B, with inhibitors

S. Rangarajan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Prothrombin complex

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and strength; results from a sub-study of the FEISTY trial

G. Morrow - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Trauma

Fibrinogen (IV)

Decision-analysis modelling of effectiveness and cost-effectiveness of thromboprophylaxis for medical inpatients

D. Horner - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Deep learning of structural variations: genomic and bioinformatic lessons from antithrombin deficiency.

B. de la Morena-Barrio - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Development and validation of a clinical prediction model for 90-day venous thromboembolism risk following total hip and total knee arthroplasty

B. Nemeth - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Development of an endothelialized in vitro thrombosis model with a disease relevant extracellular matrix

A. Drysdale - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Diagnostic Potential of Rapid Automated ADAMTS13 Inhibitor Screening and Quantification

G. Moore - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved